Nykode Therapeutics AS (OSL: NYKD)

Market Cap	857.51M
Revenue (ttm)	46.02M
Net Income (ttm)	-393.85M
Shares Out	326.55M
EPS (ttm)	-1.37
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	875,693
Average Volume	1,770,493
Open	2.640
Previous Close	2.622
Day's Range	2.556 - 2.690
52-Week Range	1.550 - 20.040
Beta	1.30
RSI	39.95
Earnings Date	Feb 26, 2025

About Nykode Therapeutics AS

Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies. The company develops vaccines for the treatment cancer and infectious diseases. Its lead product candidates include VB10.NEO, a cancer neoantigen vaccine, which is in phase I/IIa clinical trial for the treatment of ,melanoma, lung, bladder, renal, head, and neck cancer; VB10.16, a therapeutic vaccine, which in phase II clinical trial for the treatment of human papilloma virus 16 induced malignancies, such as cervical cancer; and VB1...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2006
• Employees: 173
• Stock Exchange: Oslo Børs
• Ticker Symbol: NYKD

Financial Performance

In 2023, Nykode Therapeutics AS's revenue was $13.32 million, an increase of 47.56% compared to the previous year's $9.03 million. Losses were -$35.15 million, -17.75% less than in 2022.

Financial numbers in USD